Overview
Olga Ilkayeva, Ph.D., is the Director of the Metabolomics Core Laboratory at Duke Molecular Physiology Institute. She received her Ph.D. training in Cell Regulation from UT Southwestern Medical Center at Dallas, TX. Her postdoctoral research in the laboratory of Dr. Chris Newgard at Duke University Medical Center focused on lipid metabolism and regulation of insulin secretion. As a research scientist at the Stedman Nutrition and Metabolism Center, Dr. Ilkayeva expanded her studies to include the development of targeted mass spectrometry analyses. Currently, she works on developing and validating quantitative mass spectrometry methods used for metabolic profiling of various biological models with emphasis on diabetes, obesity, cardiovascular disease, and the role of gut microbiome in both health and disease.
Current Appointments & Affiliations
Assistant Professor in Medicine
·
2020 - Present
Medicine, Endocrinology, Metabolism, and Nutrition,
Medicine
Member of Duke Molecular Physiology Institute
·
2020 - Present
Duke Molecular Physiology Institute,
Institutes and Centers
Recent Publications
Acute perioperative alterations in metabolism: A pilot study using mass spectrometry-based metabolomics.
Journal Article Surgery · April 2025 OBJECTIVE: To characterize early physiologic stresses imposed by surgery by applying metabolomic analyses to deeply phenotype pre- and postoperative plasma and urine of patients undergoing elective surgical procedures. BACKGROUND: Patients experience perio ... Full text Link to item CitePathway Coessentiality Mapping Reveals Complex II is Required for de novo Purine Biosynthesis in Acute Myeloid Leukemia.
Journal Article bioRxiv · March 2, 2025 Understanding how cellular pathways interact is crucial for treating complex diseases like cancer, yet our ability to map these connections systematically remains limited. Individual gene-gene interaction studies have provided insights 1,2 , but they miss ... Full text Link to item CiteMetabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEF.
Journal Article JACC Basic Transl Sci · March 2025 Growing evidence supports therapeutic ketosis in heart failure with reduced ejection fraction, though uncertainty exists regarding use with SGLT2i and dose-dependent effects. In a phase I trial of 2 ketone ester (KE) doses in 20 heart failure with reduced ... Full text Link to item CiteRecent Grants
The Role of RBC Reactive Oxygen Species in Regulating Thrombotic Events During Aging
ResearchCollaborator · Awarded by National Institutes of Health · 2021 - 2026NCDRC P&F April 2022
ResearchCollaborator · Awarded by Wake Forest University · 2021 - 2023KLF15 in Skeletal Muscle Lipid Metabolism
ResearchPrincipal Investigator · Awarded by Case Western Reserve University · 2017 - 2022View All Grants
Education, Training & Certifications
University of Texas Southwestern Medical Center, Medical School ·
2002
Ph.D.